Matrix metalloproteinase (MMP)-9: A proximal biomarker for cardiac remodeling and a distal biomarker for inflammation

Pharmacology and Therapeutics

Volumn 139, Issue 1, 2013, Pages 32-40

  Halade, Ganesh V ^a   Jin, Yu Fang ^a,b   Lindsey, Merry L ^a,c,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cardiovascular; Congestive heart failure; Inflammation; MMP 9; Myocardial infarction

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANTHRACYCLINE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CD40 LIGAND; COLLAGENASE 3; DOXYCYCLINE; GELATINASE B; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; STROMELYSIN; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL AORTA ANEURYSM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; GENETIC ASSOCIATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE WALL; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MORTALITY; NEOPLASM; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASE 9; VENTRICULAR REMODELING;

EID: 84877924467     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.03.009     Document Type: Review

References (115)

1. D. Ahrens, A.E. Koch, R.M. Pope, M. Stein-Picarella, and M.J. Niedbala Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis Arthritis Rheum 39 1996 1576 1587
2. P.B. Balagopal, S.D. de Ferranti, S. Cook, S.R. Daniels, S.S. Gidding, and L.L. Hayman Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association Circulation 123 2011 2749 2769
3. G.A. Bannikov, T.V. Karelina, I.E. Collier, B.L. Marmer, and G.I. Goldberg Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide J Biol Chem 2002 M110931200
4. U. Benbow, and C.E. Brinckerhoff The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 15 1997 519 526
5. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
6. S. Blankenberg, H.J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, and G. Hafner Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585
7. E. Braunwald Biomarkers in heart failure N Engl J Med 358 2008 2148 2159
8. A.L. Chancey, G.L. Brower, J.T. Peterson, and J.S. Janicki Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload Circulation 105 2002 1983 1988
9. Y.A. Chiao, Q. Dai, J. Zhang, J. Lin, E.F. Lopez, and S.S. Ahuja Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging Circ Cardiovasc Genet 4 2011 455 462
10. F. Cipollone, A. Iezzi, M. Fazia, M. Zucchelli, B. Pini, and C. Cuccurullo The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control Circulation 108 2003 1070 1077
11. M.L. Coker, J.R. Jolly, C. Joffs, T. Etoh, J.R. Holder, and B.R. Bond Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation Am J Physiol Heart Circ Physiol 281 2001 H543 H551
12. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89 2001 201 210
13. R. de Nooijer, C.J. Verkleij, J.H. von der Thusen, J.W. Jukema, E.E. van der Wall, and T.J. van Berkel Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis Arterioscler Thromb Vasc Biol 26 2006 340 346
14. M. Dobaczewski, C. Gonzalez-Quesada, and N.G. Frangogiannis The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction J Mol Cell Cardiol 48 2010 504 511
15. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nat Rev Immunol 11 2011 98 107
16. A. Ducharme, S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, and L.E. Rohde Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction J Clin Invest 106 2000 55 62
17. M. Egeblad, and Z. Werb New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 2002 161 174
18. T. Etoh, C. Joffs, A.M. Deschamps, J. Davis, K. Dowdy, and J. Hendrick Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs Am J Physiol Heart Circ Physiol 281 2001 H987 H994
19. L. Fang, X.J. Du, X.M. Gao, and A.M. Dart Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction Clin Sci 119 2010 175 183
20. L. Fang, X.M. Gao, X.L. Moore, H. Kiriazis, Y. Su, and Z. Ming Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction J Mol Cell Cardiol 43 2007 535 544
21. M. Fertin, E. Dubois, A. Belliard, P. Amouyel, F. Pinet, and C. Bauters Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction Am J Cardiol 110 2012 277 283
22. J. Figueras, J. Cortadellas, and J. Soler-Soler Left ventricular free wall rupture: clinical presentation and management Heart 83 2000 499 504
23. S.P. Fortmann, E. Ford, M.H. Criqui, A.R. Folsom, T.B. Harris, and Y. Hong CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group Circulation 110 2004 e554 e559
24. S. Frantz, J. Bauersachs, and G. Ertl Post-infarct remodelling: contribution of wound healing and inflammation Cardiovasc Res 81 2009 474 481
25. X.M. Gao, Q. Xu, H. Kiriazis, A.M. Dart, and X.J. Du Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology Cardiovasc Res 65 2005 469 477
26. R.E. Gerszten, A. Asnani, and S.A. Carr Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics Circ Res 109 2011 463 474
27. A. Goetzenich, N. Hatam, A. Zernecke, C. Weber, T. Czarnotta, and R. Autschbach Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig J Heart Lung Transplant 28 2009 1087 1093
28. R.J. Goldberg, J. Ciampa, D. Lessard, T.E. Meyer, and F.A. Spencer Long-term survival after heart failure: a contemporary population-based perspective Arch Intern Med 167 2007 490 496
29. P.J. Gough, I.G. Gomez, P.T. Wille, and E.W. Raines Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice J Clin Invest 116 2006 59 69
30. Z. Gu, M. Kaul, B. Yan, S.J. Kridel, J. Cui, and A. Strongin S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death Science 297 2002 1186 1190
31. F.R. Gutierrez, M.M. Lalu, F.S. Mariano, C.M. Milanezi, J. Cena, and R.F. Gerlach Increased activities of cardiac matrix metalloproteinases matrix metalloproteinase (MMP)-2 and MMP-9 are associated with mortality during the acute phase of experimental Trypanosoma cruzi infection J Infect Dis 197 2008 1468 1476
32. J. Hansson, R.S. Vasan, J. Arnlov, E. Ingelsson, L. Lind, and A. Larsson Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study PLoS One 6 2011 e16185
33. K.A. Hasty, T.F. Pourmotabbed, G.I. Goldberg, J.P. Thompson, D.G. Spinella, and R.M. Stevens Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases J Biol Chem 265 1990 11421 11424
34. S. Heymans, A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, and L. Moons Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure Nat Med 5 1999 1135 1142
35. M.A. Hlatky, E. Ashley, T. Quertermous, D.B. Boothroyd, P. Ridker, and A. Southwick Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease Am Heart J 154 2007 1043 1051
36. M.A. Hlatky, P. Greenland, D.K. Arnett, C.M. Ballantyne, M.H. Criqui, and M.S. Elkind Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
37. T.B. Horwich, and G.C. Fonarow Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure J Am Coll Cardiol 55 2010 283 293
38. M.P. Hudson, P.W. Armstrong, W. Ruzyllo, J. Brum, L. Cusmano, and P. Krzeski Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial J Am Coll Cardiol 48 2006 15 20
39. J.L. Johnson, L. Devel, B. Czarny, S.J. George, C.L. Jackson, and V. Rogakos A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice Arterioscler Thromb Vasc Biol 31 2011 528 535
40. J.L. Johnson, S.J. George, A.C. Newby, and C.L. Jackson Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries Proc Natl Acad Sci U S A 102 2005 15575 15580
41. S. Jonsson, A. Lundberg, H. Kalvegren, I. Bergstrom, A. Szymanowski, and L. Jonasson Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris PLoS One 6 2011 e19340
42. N.P. Kadoglou, and C.D. Liapis Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms Curr Med Res Opin 20 2004 419 432
43. R. Kawakami, Y. Saito, I. Kishimoto, M. Harada, K. Kuwahara, and N. Takahashi Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction Circulation 110 2004 3306 3312
44. D. Kelly, G. Cockerill, L.L. Ng, M. Thompson, S. Khan, and N.J. Samani Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study Eur Heart J 28 2007 711 718
45. N. Kobayashi, N. Hata, N. Kume, S. Yokoyama, T. Shinada, and K. Tomita Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome Circ J 75 12 2011 2853 28561 (Epub 2011 Oct 1)
46. Y. Konstantino, T.T. Nguyen, R. Wolk, R.J. Aiello, S.G. Terra, and D.A. Fryburg Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease Biomarkers 14 2009 118 129
47. R. Krishna, G. Herman, and J.A. Wagner Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes AAPS J 10 2008 401 409
48. R. Krishna, and J.A. Wagner Applications of 'decisionable' biomarkers in cardiovascular drug development Biomark Med 4 2010 815 827
49. C.C. Lang, and D.M. Mancini Non-cardiac comorbidities in chronic heart failure Heart 93 2007 665 671
50. J.L. Lauer-Fields, J.K. Whitehead, S. Li, R.P. Hammer, K. Brew, and G.B. Fields Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition J Biol Chem 283 2008 20087 20095
51. H.M. Lee, S.G. Ciancio, G. Tuter, M.E. Ryan, E. Komaroff, and L.M. Golub Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug J Periodontol 75 2004 453 463
52. P. Libby, and M. Aikawa Mechanisms of plaque stabilization with statins Am J Cardiol 91 2003 4B 8B
53. M.L. Lindsey MMP induction and inhibition in myocardial infarction Heart Fail Rev 9 2004 7 19
54. M.L. Lindsey, G.P. Escobar, L.W. Dobrucki, D.K. Goshorn, S. Bouges, and J.T. Mingoia Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction Am J Physiol Heart Circ Physiol 290 2006 H232 H239
55. M.L. Lindsey, G.P. Escobar, R. Mukherjee, D.K. Goshorn, N.J. Sheats, and J.A. Bruce Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction Circulation 113 2006 2919 2928
56. M.L. Lindsey, D.K. Goshorn, C.E. Squires, G.P. Escobar, J.W. Hendrick, and J.T. Mingoia Age-dependent changes in myocardial matrix metalloproteinase/ tissue inhibitor of metalloproteinase profiles and fibroblast function Cardiovasc Res 66 2005 410 419
57. M. Lindsey, K. Wedin, M.D. Brown, C. Keller, A.J. Evans, and J. Smolen Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion Circulation 103 2001 2181 2187
58. M.L. Lindsey, and R. Zamilpa Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction Cardiovasc Ther 30 1 2012 31 41
59. J. Lopez-Sendon, E.P. Gurfinkel, E. Lopez de Sa, G. Agnelli, J.M. Gore, and P.G. Steg Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events Eur Heart J 31 2010 1449 1456
60. A. Luttun, E. Lutgens, A. Manderveld, K. Maris, D. Collen, and P. Carmeliet Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth Circulation 109 2004 1408 1414
61. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, and P. Duc Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
62. Y. Mano, T. Anzai, H. Kaneko, Y. Nagatomo, T. Nagai, and A. Anzai Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy Circ J 75 2011 1717 1727
63. R. Martos, J. Baugh, M. Ledwidge, C. O'Loughlin, C. Conlon, and A. Patle Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction Circulation 115 2007 888 895
64. R. Mukherjee, T.A. Brinsa, K.B. Dowdy, A.A. Scott, J.M. Baskin, and A.M. Deschamps Myocardial infarct expansion and matrix metalloproteinase inhibition Circulation 107 2003 618 625
65. R. Mukherjee, G.P. Colbath, C.D. Justus, J.A. Bruce, C.M. Allen, and K.W. Hewett Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury FASEB J 24 2010 3819 3828
66. R. Mukherjee, J.T. Mingoia, J.A. Bruce, J.S. Austin, R.E. Stroud, and G.P. Escobar Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction Am J Physiol Heart Circ Physiol 291 5 2006 H2216 H2228
67. H. Nagase, R. Visse, and G. Murphy Structure and function of matrix metalloproteinases and TIMPs Cardiovasc Res 69 2006 562 573
68. G. Opdenakker, P.E. Van den Steen, B. Dubois, I. Nelissen, E. Van Coillie, and S. Masure Gelatinase B functions as regulator and effector in leukocyte biology J Leukoc Biol 69 2001 851 859
69. S. Orn, C. Manhenke, I.B. Squire, L. Ng, I. Anand, and K. Dickstein Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function J Card Fail 13 10 2007 843 849
70. G.J. Peppin, and S.J. Weiss Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils Proc Natl Acad Sci U S A 83 1986 4322 4326
71. J.T. Peterson Matrix metalloproteinase inhibitor development and the remodeling of drug discovery Heart Fail Rev 9 2004 63 79
72. M.A. Pfeffer, and E. Braunwald Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications Circulation 81 1990 1161 1172
73. K.E. Porter, and N.A. Turner Cardiac fibroblasts: at the heart of myocardial remodeling Pharmacol Ther 123 2009 255 278
74. M. Ram, Y. Sherer, and Y. Shoenfeld Matrix metalloproteinase-9 and autoimmune diseases J Clin Immunol 26 2006 299 307
75. R. Ramani, M. Mathier, P. Wang, G. Gibson, S. Togel, and J. Dawson Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling Am J Physiol Heart Circ Physiol 287 2004 H1369 H1377
76. C.A. Ramseier, J.S. Kinney, A.E. Herr, T. Braun, J.V. Sugai, and C.A. Shelburne Identification of pathogen and host-response markers correlated with periodontal disease J Periodontol 80 2009 436 446
77. M.J. Reardon, C.L. Carr, A. Diamond, G.V. Letsou, H.J. Safi, and R. Espada Ischemic left ventricular free wall rupture: prediction, diagnosis, and treatment Ann Thorac Surg 64 1997 1509 1513
78. A.M. Richards What we may expect from biomarkers in heart failure Heart Fail Clin 5 2009 463 470
79. T.K. Robichaud, B. Steffensen, and G.B. Fields Exosite interactions impact matrix metalloproteinase collagen specificities J Biol Chem 286 2011 37535 37542
80. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
81. L.E. Rohde, A. Ducharme, L.H. Arroyo, M. Aikawa, G.H. Sukhova, and A. Lopez-Anaya Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice Circulation 99 1999 3063 3070
82. A.M. Romanic, C.L. Burns-Kurtis, B. Gout, I. Berrebi-Bertrand, and E.H. Ohlstein Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit Life Sci 68 2001 799 814
83. R. Ross Atherosclerosis is an inflammatory disease Am Heart J 138 1999 S419 S420
84. R. Roy, J. Yang, and M.A. Moses Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer Clin Oncol 27 31 2009 5287 5297
85. J.M. Shipley, G.A. Doyle, C.J. Fliszar, Q.Z. Ye, L.L. Johnson, and S.D. Shapiro The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats J Biol Chem 271 1996 4335 4341
86. E.K. Sim, L. Zhang, W.S. Shim, Y.L. Lim, and R. Ge Therapeutic angiogenesis for coronary artery disease J Card Surg 17 4 2002 350 354
87. S.C. Smith Jr., J.L. Anderson, R.O. Cannon III, Y.Y. Fadl, W. Koenig, and P. Libby CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group Circulation 110 2004 e550 e553
88. L. Sorokin The impact of the extracellular matrix on inflammation Nat Rev Immunol 10 2010 712 723
89. F.G. Spinale Matrix metalloproteinases: regulation and dysregulation in the failing heart Circ Res 90 2002 520 530
90. F.G. Spinale, M.L. Coker, S.R. Krombach, R. Mukherjee, H. Hallak, and W.V. Houck Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function Circ Res 85 1999 364 376
91. I.B. Squire, J. Evans, L.L. Ng, I.M. Loftus, and M.M. Thompson Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction J Card Fail 10 2004 328 333
92. M.D. Sternlicht, and Z. Werb How matrix metalloproteinases regulate cell behavior Annu Rev Cell Dev Biol 17 2001 463 516
93. J. Sundstrom, J.C. Evans, E.J. Benjamin, D. Levy, M.G. Larson, and D.B. Sawyer Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study Circulation 109 2004 2850 2856
94. D.P. Symmons, and S.E. Gabriel Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE Nat Rev Rheumatol 7 2011 399 408
95. T. Takahashi, T. Anzai, H. Kaneko, Y. Mano, A. Anzai, and T. Nagai Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction Am J Physiol Heart Circ Physiol 299 2010 H1795 H1804
96. A. Tandon, and S. Sinha Structural insights into the binding of MMP9 inhibitors Bioinformation 5 2011 310 314
97. W.H. Tang, G.S. Francis, D.A. Morrow, L.K. Newby, C.P. Cannon, and R.L. Jesse National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure Circulation 116 2007 e99 e109
98. R.M. Tanner, A.I. Lynch, V.H. Brophy, J.H. Eckfeldt, B.R. Davis, and C.E. Ford Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension PLoS One 6 2011 e23609
99. Z.Y. Tao, M.A. Cavasin, F. Yang, Y.H. Liu, and X.P. Yang Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice Life Sci 74 2004 1561 1572
100. I. Tchetverikov, L.R. Lard, J. DeGroot, N. Verzijl, J.M. TeKoppele, and F.C. Breedveld Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis Ann Rheum Dis 62 2003 1094 1099
101. R.W. Thompson, and B.T. Baxter MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial Ann N Y Acad Sci 878 1999 159 178
102. S.W. van den Borne, J.P. Cleutjens, R. Hanemaaijer, E.E. Creemers, J.F. Smits, and M.J. Daemen Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction Cardiovasc Pathol 18 2009 37 43
103. P.E. Van Den Steen, A. Wuyts, S.J. Husson, P. Proost, J. Van Damme, and G. Opdenakker Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities Eur J Biochem 270 2003 3739 3749
104. R.S. Vasan Biomarkers of cardiovascular disease: molecular basis and practical considerations Circulation 113 2006 2335 2362
105. R.S. Velagaleti, P. Gona, M.G. Larson, T.J. Wang, D. Levy, and E.J. Benjamin Multimarker approach for the prediction of heart failure incidence in the community Circulation 122 2010 1700 1706
106. F.J. Villarreal, M. Griffin, J. Omens, W. Dillmann, J. Nguyen, and J. Covell Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling Circulation 108 2003 1487 1492
107. A.T. Yan, R.T. Yan, F.G. Spinale, R. Afzal, H.R. Gunasinghe, and M. Arnold Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure J Card Fail 12 2006 514 519
108. Y. Yang, Y. Ma, W. Han, J. Li, Y. Xiang, and F. Liu Age-related differences in postinfarct left ventricular rupture and remodeling Am J Physiol Heart Circ Physiol 294 2008 H1815 H1822
109. W.M. Yarbrough, R. Mukherjee, G.P. Escobar, J.T. Mingoia, J.A. Sample, and J.W. Hendrick Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling Circulation 108 2003 1753 1759
110. Y. Yoshihara, H. Nakamura, K. Obata, H. Yamada, T. Hayakawa, and K. Fujikawa Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis Ann Rheum Dis 59 2000 455 461
111. R. Zamilpa, R. Kanakia, J.t. Cigarroa, Q. Dai, G.P. Escobar, and H.M. Martinez CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction Am J Physiol Heart Circ Physiol 300 4 2011 H1418 H1426
112. R. Zamilpa, and M.L. Lindsey Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences J Mol Cell Cardiol 48 2010 558 563
113. R. Zamilpa, E.F. Lopez, Y.A. Chiao, Q. Dai, G.P. Escobar, and K. Hakala Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction Proteomics 10 2010 2214 2223
114. Y. Zhang, Y. Gu, H.M. Lee, E. Hambardjieva, K. Vrankova, and L.M. Golub Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins Curr Med Chem 19 2012 4348 4358
115. B. Zhang, S. Ye, S.M. Herrmann, P. Eriksson, M. de Maat, and A. Evans Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis Circulation 99 1999 1788 1794